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Abstract
Purpose—During glutaminolysis, glutamine is catabolized to glutamate and incorporated into
citric acid cycle and lipogenesis. Serum glutamate levels were measured in patients with primary
prostate cancer (PCa) or metastatic castrate-resistant PCa (mCRPCa) to establish clinical
relevance. The effect of glutamate-deprivation or blockade by metabotropic glutamate receptor 1
(GRM1)-antagonists was investigated on PCa cells’ growth, migration, and invasion to establish
biological relevance.
Experimental Design—Serum glutamate levels were measured in normal men (n = 60) and
patients with primary PCa (n = 197) or mCRPCa (n = 109). GRM1 expression in prostatic tissues
was examined using immunohistochemistry (IHC). Cell growth, migration, and invasion were
Request for reprints: Shahriar Koochekpour, Departments of Cancer Genetics and Urology, Center for Genetics and Pharmacology,
Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY. Phone: 716-845-3345; Fax: 716-845-1698;
Shahriar.Koochekpour@Roswellpark.org.
Disclosure of Potential Conflict of Interest: No potential conflicts of interest were disclosed.
NIH Public Access
Author Manuscript
Clin Cancer Res. Author manuscript; available in PMC 2013 November 01.
Published in final edited form as:










determined using cell cytotoxicity and modified Boyden chamber assays, respectively. Apoptosis
was detected using immunoblotting against cleaved caspases, PARP and γ-H2AX.
Results—Univariate and multivariate analyses demonstrated significantly higher serum
glutamate levels in Gleason score ≥ 8 than in the Gleason sscore ≤ 7 and in African Americans
than in the Caucasian Americans. African Americans with mCRPCa significantly higher serum
glutamate levels than those with primary PCa or benign prostate. However, in Caucasian
Americans, serum glutamate levels were similar in normal research subjects and patients with
mCRPC. IHC demonstrated weak or no expression of GRM1 in luminal acinar epithelial cells of
normal or hyperplastic glands, but high expression in primary or metastatic PCa tissues. Glutamate
deprivation or blockade decreased PCa cells’ proliferation, migration, and invasion and led to
apoptotic cell death.
Conclusions—Glutamate expression is mechanistically associated with and may provide a
biomarker of PCa aggressiveness.
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Prostate cancer (PCa) is estimated to account for 29% of all new cancers and is the second
leading cause of cancer-related death in men in the United States in 2012 (1). Age, African-
American race, and family history are unequivocal risk factors for PCa (2). Focusing on
early detection of PCa has the capacity to decrease PCa mortality. Serum prostate-specific
antigen (PSA) is used for PCa early detection, but its use is controversial because of its
sensitivity and specificity is limited and it does not provide reliable prognostic information.
These limitations have led investigators to consider new approaches, using systems biology,
to identify biomarkers of PCa aggressiveness. This goal could be reached by defining
important interacting cellular networks and/or metabolic pathways that reflect tissue- and
disease-specific phenotypes.
Metabolomics has emerged recently as a promising method for PCa detection (3), one that
may supplement, or even replace current PSA testing. Metabolomics profiling of PCa offers
the potential for early detection and discrimination of clinically aggressive tumors from
indolent and non-aggressive diseases. Metabolic changes are affected by genetic and
epigenetic changes and a long list of environmental factors, which include diurnal variation,
dietary habits, and lifestyle. The prostate is a unique target for metabolomics analysis both
under normal conditions and upon neoplastic transformation. Extremely high amounts of
citrate are produced and secreted by the prostate that reflects the unique state of anabolic and
catabolic processes of secretory luminal cells. Citrate metabolism differs in PCa compared
to benign prostatic hyperplasia (BPH) (4).
Glutamate is a non-essential amino acid and an excitatory neurotransmitter that is involved
in neuroembryoinc growth and development by regulating proliferation, survival, migration,
and invasion of neuronal progenitors and immature neurons (5). A prominent consequence
of signaling in rapidly proliferating cancer cells is increased nutrient uptake. Glucose and
glutamine are the two most abundant nutrients in mammals. During glycolysis and
glutaminolysis, glucose is converted to lactate and glutamine to glutamate, respectively (6).
In addition to being a precursor of other amino acids and nucleotides, glutamate metabolism
is closely linked to ureagenesis, glutathione synthesis, tricarboxylic acid cycle (TCA), amino
acid transferase, GABA synthesis, lipogenesis, and ATP production (6). More than 80 years
ago, Otto Warburg demonstrated aerobic glycolysis in tumor cells by their high rate of
wasteful glucose consumption, increased lactate production, and bioenergetics demand
despite accessibility to oxygen (7). This shift from mitochondrial ATP production was later
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proved to be a hallmark of aggressive tumors and rapidly proliferating non-transformed
cells, such as lymphocytes, thymocytes, and erythrocytes (8). In the PC-3 PCa cell line, c-
Myc oncogenic transcription increases mitochondrial glutaminase expression that leads to
enhanced glutaminolytic activity, catabolic conversion of glutamine to glutamate and
glutamine addiction (9). Taylor et al demonstrated elevated levels of glutamate in 12 PCa
compared with 16 BPH tissues and increased levels of additional metabolites in the urea
cycle using high throughput quantitative humoral response profiling (10). Glutamate levels
were higher in the majority of PCa patients than in BPH tissues in a follow-up study by the
same group (11).
Glutamate in secreted form is a phylogenetically conserved cell signaling molecule in
addition to its intracellular activities in bioenergetics, biosynthetic pathways, maintaining
amino acids and nucleotide pool, and metabolism (12). The glutamatergic system comprises
the glutamate, glutamate receptors (GluRs), and glutamate transporters. The GluRs are
divided into two different categories: the ionotropic glutamate receptors (iGluRs) and the
metabotropic glutamate receptors (mGluRs) (13). The iGluRs are gated ion channels with
excitatory action (13). The mGluRs promote cellular signaling pathways via seven
transmembrane domain G-protein coupled receptors (GPCRs) and are subdivided into three
groups and eight subtypes: group I (mGluR1 and mGluR5), II (mGluR2 and mGluR3), and
III (mGluR4,mGluR6, mGluR7, and mGluR8) based on their pharmacology, sequence
homology, response to agonists, and downstream signaling. mGluRs are expressed in a
variety of non-neuronal cell types, such as hepatocytes, melanocytes, keratinocytes,
myocardial cells, pancreatic cells, and embryonic stem cells (14, 15). Recently, several
studies have indicated the involvement of mGluRs in tumorigenesis. mGluRs are highly
overexpressed in the nervous system, so initial discoveries of mGluRs in human tumors
were reported in neuro-glial derived tumors such as gliomas, neuroblastoma, and
medulloblastoma (14, 15). Glioma cells secreting high amounts of glutamate have higher
growth rates than their isogenic parental cells (16). Glutamate antagonists decreased
proliferation of a variety of cancer cells which include colon adenocarcinoma, melanoma,
lung carcinoma, thyroid carcinoma, breast carcinoma, astrocytoma, neuroblastoma, and
rhabdomyosarcoma (17). The first proof for the involvement of mGluRs in non-neuronal
tumorigenesis was obtained by Chen et al (18, 19). A transgenic mouse line overexpressing
mGluR1 (also known as GRM1) in melanocytes was predisposed to spontaneous melanoma
development with 100% penetrance, short latency, and high metastatic potential (18,19). In
PCa, mGluR1-5 mRNA expression was reported in PC-3 and LNCaP cells and mGluR6 and
8 were expressed only in LNCaP cells. DHT induced mGluR7 expression and inhibited
mGluR8 expression in LNCaP cells (20). The clinical significance or biological relevance of
glutamate in PCa has not been investigated.
In this study, we examined the association between serum glutamate levels and PCa
aggressiveness to establish clinical relevance. To determine the biological relevance, the




Primary PCa cases investigated in this study refer to newly diagnosed, untreated, and
clinically localized PCa. Normal research subjects in this study are defined as men with no
evidence of PCa. Serum samples used to evaluate glutamate levels in normal individuals and
men with primary tumor or mCRPCa, were obtained from the biospecimen core facilities at
the Louisiana Cancer Research Consortium (LCRC) affiliated to Tulane Medical School and
School of Medicine, Louisiana State University Health Sciences Center (LSUHSC) and the
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tumor bank at the University of Washington Medical Center (UWMC) after informed
consent and without any personal identifiers. Briefly, peripheral blood samples were
collected by phlebotomy from consenting normal adult males or patients with primary or
mCRPCa in the Urology Oncology clinics at the UWMC and LCRC-affiliated hospitals. All
of the controls came from patients who presented at the University of Washington’s annual
free PSA screening week. All patients were above 40 years of age and all stated that they did
not have a history of prostate cancer. PSA values were below 4.0 ng/mL. Blood samples
from UWMC were processed by centrifugation and serum samples were stored in aliquots at
−80 degrees C within ≤ 4 hours of draw. Overall, all normal serum samples, 39% of primary
PCa, and 69% of mCRPCa samples were obtained from the UWMC. The remainder of
serum samples was processed similarly and obtained from the biospecimen core facilities at
LCRC. Serum samples were stored until used in the research study; no freeze-thaw cycles
were incurred. We did not acquire fasting or post meal status on any of the research subjects.
PCa aggressiveness was defined using Gleason score, clinical stage, and PSA at diagnosis
as: (a) high aggressive (Gleason sum ≥ 8, or PSA >20 ng/ml, or Gleason sum =7, and stage
cT3-cT4); (b) low aggressive (Gleason sum <7 and stage cT1-cT2 and PSA <10 ng/ml); or
(3) intermediate aggressive (all other cases) (21). The PCa tissue specimens used for IHC
were obtained from Accumax Array (Accurate Chemical & Scientific Corp, Westbury, NY).
Ethical considerations
Ethical approval was obtained from the Institutional Review Boards at University of
Washington Medical Center, Seattle, Washington, Tulane Cancer Center, Tulane University
School of Medicine, New Orleans, Louisiana, LSUHSC, School of Medicine, New Orleans,
LA, and Roswell Park Cancer Institute, Buffalo, New York, NY.
Determination of serum glutamate and creatinine levels
Serum glutamate levels were measured using BioVision’s glutamate assay kit (#K629-100,
Mountain View, CA) that provides sensitive detection method for glutamate in a variety of
biological samples and fluids including serum, urine, cells, and tissue extracts. The amount
of glutamate is quantitated by measuring optical density at λ = 450 nm in a microplate
reader. Background reading was corrected by subtracting the value from the zero glutamate
control from all samples readings. Serum creatinine concentration was measured using the
BioVision creatinine assay kit (#K625-100) and the manufacturer’s instructions. After
plotting the independent glutamate and creatinine standard curves, glutamate and creatinine
concentrations of the serum samples were calculated using the formula C=Sa/Sv nmol/μl, or
mM, where Sa is the sample amount of unknown (in nmol) from standard curve and Sv is the
sample volume (μl) added to each well.
The minimum detectable amounts for serum glutamate or creatinine were two nmol/mL. The
standard curve reproducibility was demonstrated in five independent assays. The intra-assay
variance was evaluated in ten replicates for three serum samples of known concentrations on
one plate. The inter-assay precision was tested in three independent assays for three control
samples in triplicates. Stability of serum glutamate was determined by incubating aliquots of
serum samples of known glutamate concentrations at −20 or −70°C for 3, 6, 12, 18, 24, and
36 months.
Immunohistochemical analysis
The ABC detection system (Vector Laboratories Inc.) was used for immunostaining as
described previously (22). Affinity purified, polyclonal rabbit antihuman-GRM1 antibody
(at 1:250, Sigma) was used as the primary antibody. The incubation time for primary
antibody was overnight at 4°C. The slides were counterstained with hematoxylin and
mounted for examination. The negative control slides were treated in an identical manner
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except that the primary antibodies were omitted. Descriptive examinations of cell type-
specific anti-GRM1 immunoreactivity in various tissue constituents, normal, hyperplastic,
and neoplastic glands in the sections were completed by the study pathologists.
Cell Culture, reagents, and western blot analysis
Androgen-independent (PC-3, DU145, MDA-PCa2b, VCaP, 22Rv1) and androgen-senstive
(LNCaP) PCa cell lines were purchased from American Type Culture Collection (Manassas,
VA) and maintained in their individually specified medium (23). E006AA cell line was
maintained in DMEM supplemented with 10% FBS (23). Non-competitive GRM1
antagonists (Riluzole and BAY36-7620) were purchased from Tocris (Ellisville, MO) (24).
Customized glutamine- and glutamate-free RPMI-1640 or DMEM, dialyzed FBS, and
GlutaMax™-I (a dipeptide, L-alanine-L-glutamine) were purcased from Life Technologies
(Grand Island, NY). GlutaMAX was used as a substitute for glutamine in cell growth, which
cannot be degraded or converted into glutamate. Cells were cultured in complete media up
to 75% confluency, washed with cold PBS, and whole cell lysates were extracted as
described previously (23). GRM1 was detected using a rabbit polyclonal antibody against
human GRM1 (Cat # 19955-1-AP at 1:1000; Proteintech Group Inc, Chicago, IL) using
ECL detection system (GE Healthcare Biosciences, Pittsburgh, PA). The anti-GRM1
specificity was examined by probing the duplicate membrane with primary antibody that
was pre-incubated with GRM1-specific blocking peptide (Proteintech Group Inc, Chicago,
IL) at 5 μg/ml for 2 hours with rotation at room temperature. Detection of apoptosis markers
was performed using immunoblotting. Cells were cultured up to 50% confluency in
complete culture media in the presence or absence of DMSO or riluzole at 0, 10, 25, or 50
μM for 4 or 6 days and whole cell lysates were prepared. Clarified protein samples (35 μg)
were subjected to SDS-PAGE under reducing conditions. Western analyses were carried out
using monoclonal antibodies against cleaved caspases-9, -7, and -3 and poly (ADP-ribose)
polymerase (PARP) provided in an Apoptosis Sampler Kit (Cell Signaling Technology) and
phosphorylated histone H2AX Ser 139 (γ-H2AX). Anti-GAPDH (at 1:5000; Cell Signaling
Technology, Boston, MA) was used for loading controls. Each experiment was performed in
duplicate, and the assays were repeated three times.
Cell proliferation assays
PCa cells growth was examined in the presence of GRM1 (mGluR1) antagonists, riluzole
and BAY36-7620. Riluzole functions in part by blocking GRM1 signaling and preventing
intracellular glutamate release. BAY 36-7620 is a specific non-competitive antagonist of
GRM1 that binds the transmembrane domain of the receptor and stabilizes its inactive
transformation (24). Cells were seeded at 500 (PC-3, DU145, LNCaP) per 200 μl/well and
in 24 replicates in 96-well plates in complete medium. After 3 days culture medium was
refreshed and supplemented with DMSO, riluzole, or BAY36-7620 at 0, 1, 10, 25, or 50
μM. Culture plates were incubated at 37°C for 2, 4, or 6 days and the media were refreshed
every 48 h. Cell proliferation was measured using The CellTiter 96® AQueous One Solution
Cell Proliferation Assay (Promega, Madison, WI).
PCa cell growth under glutamine- and glutamate-free condition was examined in an
independent set of 96-well plates and at cell densities described above. Cells were incubated
in customized glutamine- and glutamate-free culture media supplemented with 10%
dialyzed FBS and 2 mM GlutaMAX ™ for 3, 5, or 7 days and the media were refreshed
every 48 h. After the indicated incubation times, cell proliferation was measured as
described above and compared with their parallel isogenic cell lines cultured simultaneously
but in their complete growth medium.
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Cell migration and invasion assays
Cell migration and invasion assays were performed using 8-μm transwell filters (Costar,
Corning, NY) with the modifications described previously (25). For the invasion assay, the
upper compartment was coated with 50 μg Matrigel (BD Biosciences, San Jose, CA) to
form a matrix barrier. A suspension of cells (5 × 104 for PC-3 or 2 × 104 for DU145) in
basal medium containing 0.1% BSA was added to the upper compartment. The lower
compartment was filled with 400 μl basal medium containing 10% FBS as chemoattractant.
Riluzole or BAY36-7620 was included at equimolar concentrations (0 to 50 μM) to upper
and lower compartments. After 48 h for PC-3 or 24 h for DU145, the non-migratory cells on
the upper surface were removed using a cotton swab and the cells on the lower surface were
fixed and stained with Diff-Quick solution (Dade Behring, Deerfield, Illinois). Migrated or
invaded cells in transwell filters were counted from ten randomly selected fields in at least
four independent wells. The experiment was repeated three times independently.
Statistical design and data analysis
All analyses were performed using SAS 9.3 (SAS Institute, Cary NC) with a nominal
significance level of 0.05. The serum samples were stratified by clinical status of the
research subjects (normal, primary PCa, or mCRPCa) with patient demographics (e.g., age,
race) reported as mean and standard deviation for continuous variables, and as frequencies
and relative frequencies for categorical variable (Supplementary Table S1and S2). Patients
with primary PCa were divided to three subgroups of aggressiveness (low aggressiveness,
intermediate aggressiveness, high aggressiveness) using clinical criteria as described in
“Materials and Methods”. The demographic variables were compared between normal
research subjects and men with primary PCa or mCRPCa using one-way ANOVA and an
extension of Fisher’s exact test for continuous and categorical variables, respectively. Age,
PSA and Gleason scores were categorized as: 40-49, 50-59, 60-69, 70-79; ≤4, 4.1-10, ≥10.1;
and ≤ 6, 7, ≥ 8, respectively.
Serum glutamate levels were compared for variables of interests and among the research
subjects using one-way ANOVA, with Tukey adjusted post-hoc pair-wise comparisons. All
serum samples measurements were log-transformed prior to statistical analysis. Simple
linear regression models were used to assess the association between research subject’s
serum glutamate and clinical status (normal, primary PCa with low-, intermediate, or –high
aggressiveness score, mCRPCa) while adjusting for demographic covariates. Tukey adjusted
pair-wise comparisons were made between clinical status of research subjects and their
demographic strata when appropriate. The covariate adjusted models considered a single
demographic covariate (with and without interactions) as well as multiple demographic
covariates, as this information is not applicable or available for normal research subjects and
mCRPCa patients. Only research subjects with primary PCa were considered when Gleason
score and stage were included as covariates. All model assumptions were verified
graphically using Quantile-Quantile (QQ) and residual plots.
Results
Serum glutamate levels in normal and prostate cancer research subjects
The research subjects’ race, Gleason scores, PSA values, age and clinical aggressiveness
were described in Supplementary Table S1. Serum creatinine values were within the
expected range and did not differ significantly among research subject subgroups. Serum
PSA levels were found to be significantly (P < 0.001) different among normal individuals
(0.556 ± 0.03), patients with primary PCa (10.38 ± 2.19), and patients with mCRPCa
(323.74 ± 51.43). The average age was found to be significantly higher (P < 0.001) in
research subjects with mCRPCa (70.2 ± 1.0) than in those with primary PCa (62.0 ± 0.6) or
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normal research subjects (61.4 ± 1.2). Serum glutamate levels were not significantly
different among different age groups of normal research subjects (Supplementary Table S2,
P = 0.1735).
The entire study cohort was analyzed regardless of age and race. When the normal research
subjects (n = 60) used for comparison, serum glutamate levels significantly increased in men
with primary PCa (n = 197, P = 0.003), but returned to normal levels in men with mCRPCa
(n = 109, P = 0.002) (Fig. 1A, left). When the primary PCa patients were divided into low,
intermediate, and high aggressiveness, glutamate levels were significantly different: (a)
between normal research subjects and intermediate (P < 0.001) or high aggressiveness (P <
0.001); (b) between low aggressiveness group and intermediate (P < 0.002) or high
aggressiveness (P < 0.001) groups; (c) between intermediate aggressiveness group and
mCRPCa (P < 0.001), and (d) between high aggressiveness and mCRPCa (P < 0.001) (Fig.
1A, middle). Pairwise comparisons indicated a significant association between glutamate
levels and Gleason score (P < 0.001). Glutamate levels differed significantly between
Gleason ≤ 6 (n = 81) and Gleason 7 (n = 72; P < 0.001) or Gleason ≥ 8 (n = 30, P < 0.001).
Glutamate levels were higher in Gleason ≥ 8 than the Gleason 7 groups, but the difference
did not reach statistical significance (P < 0.064) (Fig. 1A, right). Univariate analyses, after
adjusting for PSA or stage, revealed no significant association between serum glutamate
levels and any of the three aggressiveness categories in the pool of research subjects with
primary PCa (Table 1).
The association between PCa aggressiveness and serum glutamate were explored among
primary PCa research subjects while adjusting for potential confounders. Age, PSA, and
stage did not appear to be confounders in the single and two covariate (confounder) models;
they were non-significant and did not change the direction or significance of the relationship
between serum glutamate levels and PCa aggressiveness. However, the inclusion of Gleason
score appeared to over-power the relationship between serum glutamate levels and PCa
aggressiveness. The Gleason score appeared to drive the difference between serum levels
within the primary PCa research subjects (Table 1 and 2).
Serum glutamate levels in Caucasian Americans versus African Americans
The adjusted analysis involving race indicated that patient clinical status (primary or
mCRPCa; P < 0.001), race (P = 0.029) and interaction (P = 0.029) effects were significant
(Table 1). The pair-wise comparisons of race within each clinical subgroup of research
subjects indicated that a significant difference exists in patients with mCRPCa (P < 0.037).
Figure S1 demonstrates that this difference is the result of the significant interaction term,
where serum glutamate decreases for Caucasians from the high aggressiveness to mCRPCa,
but increase for African Americans.
Among Caucasian Americans, pair-wise comparisons indicated that significant differences
in serum glutamate existed between research subjects with primary PCa and mCRPCa (P <
0.030) (Fig. 1B, left), between normal research subjects and those with PCa of high
aggressiveness (P < 0.004), between low and high aggressiveness subgroups (P = 0.001),
and between mCRPCa and high aggressiveness subgroups (P < 0.001) (Fig. 1B, middle).
Among Caucasian American research subjects with primary PCa, a significant difference
was found between research subjects with Gleason score ≤ 6 and Gleason score 7 (P <
0.002) and between Gleason score ≤ 6 and Gleason score ≥ 8 (P < 0.001) (Fig. 1B, right).
Among African Americans, pair-wise comparisons indicated that serum glutamate levels
differed between normal research subjects and primary PCa (P < 0.026) and mCRPCa (P <
0.016) (Fig. 1C, left). A significant difference in serum glutamate was found in African
Americans between the normal research subjects and intermediate aggressiveness subgroup
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(P < 0.014) and between normal and both high aggressiveness subgroup (P < 0.027) and
mCRPCa (P < 0.038) patients (Fig. 1C, middle). Among African-American research
subjects with primary PCa, significant differences in serum glutamate levels were found
between research subjects with Gleason score ≤ 6 or Gleason score ≥ 8 (P < 0.02) (Fig. 1C,
right). The serum glutamate levels differed significantly between the races only in the
research subjects with mCRPCa (P=0.037; Supplementary Fig. S1).
Immunohistochemical staining of metabotropic glutamate receptor 1 (GRM1) in benign
and malignant prostate tissues
Specificity of anti-GRM1 immuno-reactivity was demonstrated by deleting the primary
antibody or replacing it with a non-immune serum (data not shown). Basal cells exhibited
nuclear staining whereas no staining was found in luminal acinar epithelial cells of BPH or
normal prostate (n=10; Fig. 2A). Endothelial cells, infiltrating macrophages, and stromal
cells exhibited intense nuclear staining (Fig. 2A, mesenchymal cells). Intense cytoplasmic
and nuclear staining was observed in proliferating epithelial cells of glands with basal cell
hyperplasia (Supplementary Fig. S2). Moderate to intense cytoplasmic staining was noted in
high-grade prostate intraepithelial neoplasia (HGPIN) (Fig. 2A). To further determine the
GRM1 expression during PCa progression and metastasis, we carried out additional IHC
staining in primary (n = 15) and metastatic PCa tissues (n = 6). Moderate to intense
cytoplasmic staining with perinuclear enhancement was noted in Gleason score 6 and 7 PCa
(Fig. 2A). Intense cytoplasmic staining with perinuclear enhancement was also observed in
malignant acinar cells of Gleason score 8 (4+4), 9, and 10 (Fig. 2A) tumors. PCa cells
invading into extraprostatic adipose and muscular tissues exhibited intense cytoplasmic
staining (Fig 2A). Intense nuclear staining was observed at tumor-inflammatory interfaces in
inflammatory cells, endothelial cells, and isolated macrophages (Fig 2A). Intense
cytoplasmic staining was found in multi-layer PCa cells infiltrating around nerves (Fig. 2A).
Intense cytoplasmic staining with perinuclear enhancement was detected in PCa cells
metastatic to bone and the abdominal wall (Fig. 2A and Supplementary Fig. S3). GRM1
staining appeared to be distributed in both nuclear and cytoplasmic compartments. The
nuclear staining of GRM1 was heterogeneous.
GRM1 expression in prostate cancer cell lines
An affinity purified anti-GRM1 antibody detected a strong band at ~ 85 kDa (Fig. 2B) and
three other weakly expressing bands at ~ 40, ~60, and ~ 170 KDa, which were close to the
predicted bands based on GRM1 molecular weight described by the manufacturer. Parallel
immunoblotting with anti-GRM1 antibody pre-absorbed by its immunogenic peptide
confirmed specificity (Fig. 2B).
GRM1 expression in androgen-sensitive LNCaP cells was less than androgen-independent
PC-3, DU145 and androgen-independent and bone metastatic PCa cell lines (i.e., MDA-PCa
2b and VCaP). GRM1 expression in the E006AA cell line obtained from an organ-confined
Gleason 6 score PCa from an African-American was less than bone-metastatic MDA-PCa2b
cells (Fig. 2B). GRM1 expression in 22Rv1 cells was higher than LNCaP cells.
Prostate cancer cells growth in glutamate-free culture condition
Proliferation of PC-3 cells was decreased by 42%, DU145 cells by 63%, and LNCaP cells
by 68%, as compared to their isogenic control cell types after culturing 3, 5, or 7 days in
customized glutamine- and glutamate-free medium supplemented with dialyzed FBS and
GlutaMAX (Fig. 3A).
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Inhibition of PCa cell proliferation by GRM1 antagonists
To evaluate the potential of intracellular glutamate levels on PCa cells growth, we used
riluzole which functions in part as the glutamate release inhibitor (14, 15). Inhibition of
glutamate release in a cell type-, dose-, and time-dependent manner decreased PCa cells
growth (Fig. 3B). LNCaP cells were the most sensitive among the PCa cell lines
investigated. LNCaP cells growth was reduced by 54% (day 2) and by 85% (day 6)
compared with their control cell type at the same incubation period (Fig. 3B, right). Among
all PCa cells, DU145 cells were least sensitive to riluzole (Fig. 3B, middle). Proliferation of
DU145 cells was decreased by 14% (day 2) and by 18% (day 6). However, PC-3 growth
was decreased by 10% (day 2) and by 40% on day 6 (Fig. 3B, left).
To demonstrate GRM1 responsiveness as a functional glutamate receptor, independent
studies were performed using BAY36-7620 as a non-competitive GRM1 antagonist at
different concentrations and for a period of 2 to 6 days. As in the riluzole study, cells were
maintained in their complete medium containing non-dialyzed FBS and L-glutamine (2mM).
BAY36-7620 showed similar growth inhibitory effect on the three PCa cell lines and
LNCaP cells were found to be the most sensitive cell line (Supplementary Fig. S4).
Glutamate blockade induces apoptotic cell-death
The expression of cleaved (active) forms of the initiator caspase-9 and its active downstream
effectors (caspases-7 and –3) were determined in the cells grown in the presence of riluzole
for 4 or 6 days. The expression of cleaved caspase-9, -7, and -3 increased in a cell type-
specific and dose-dependent manner in all cells investigated (Fig. 3C). In general, riluzole
induced a cell type-specific increase in the expression level of initiator and effector
caspases.
The intensity of cleaved-PARP expression increased in a dose-dependent manner in all PCa
cell lines. H2AX, a member of H2A histone family is phosphorylated on serine residue 139
(known as γ-H2AX) after the activation of the caspase cascade and as a result of apoptotic
DNA fragmentation (26). Cell lysates showed a dose-dependent increase in phospho-
H2AXSer139 levels in LNCaP cells (Fig. 3C). An increase in γ-H2AX levels was also
detected at 50 μM riluzole in PC-3 and DU145 cells. Accumulation of intracellular
glutamate levels secondary to riluzole treatment appeared to be apoptogenic.
Glutamate blockade decreases PCa cells migration and invasion
Addition of riluzole or BAY36-7620 to both upper and lower compartments of transwell
filters decreased cell motility and invasion in a dose-dependent manner in PC-3 and DU145
cells (Fig. 4A and B). Riluzole reduced migration of PC-3 cells by 53% and DU145 cells by
76% and invasion of PC-3 by 65% and DU145 by 82% (Fig. 4A and B). BAY36-7620
decreased migration of PC-3 cells by 67%, DU145 cells by 88% and invasion of PC-3 by
83%, and DU145 by 96% (Fig. 4A). Similar data was obtained using a wound assay
(Supplementary Fig. S5A-C).
Discussion
Serum glutamate levels positively correlated with Gleason score and PCa aggressiveness.
IHC staining showed weak or no expression of GRM1 in luminal acinar cells of normal or
benign glands, but high expression levels in primary and metastatic PCa tissues. Glutamate
deprivation or blockade with GRM1 antagonists decreased PCa cells growth, migration, and
invasion and led to apoptotic cell death.
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Glycolysis and glutaminolysis are major contributing metabolic pathways of tumorigenesis.
Glutamine is the most abundant serum amino acid and a necessary metabolic precursor for
other amino acids and nucleotides. Glutamine deprivation decreased cell proliferation, DNA
synthesis, and protein synthesis rates in a cell type-dependent manner in hepatocellular
carcinoma and several breast and colon adenocarcinoma cells (27). Similarly, the
importance of glutamate signaling in cancer has been revealed by antiproliferative activity
of glutamate antagonists in different types of human tumor cells, such as melanoma, colon
adenocarcinoma, breast carcinoma, astrocytoma, and lung carcinoma (17).
Humoral response profiling of serum samples by Taylor et al revealed elevated levels of
nitrogen metabolism during PCa progression (10). Concomitant validation of increased
levels of the constituents of nitrogen metabolism pathway was determined further by using
high throughput quantitative profiling of relative levels of metabolites in BPH (n = 16) and
organ-confined PCa (n = 12) tissues. This study revealed significantly increased levels of
glutamate in the PCa tissues (P = 0.0003) compared to BPH. Further examination of
metabolomic changes during PCa progression by the same group verified elevated levels of
glutamate in a majority of PCa tissues as compared with benign glands (11).
The excess amount of glutamate in PCa tissues and patients’ serum may be explained by: (a)
increased rate of glutaminolysis or glutamine addiction in proliferating PCa cells and (b)
carboxypeptidase function of prostate-specific membrane antigen (PSMA) overexpressed by
PCa cells. While “glutamine addiction” serves as a non-specific metabolic hallmark of
malignant and proliferating cells, it is likely that the known enzymatic activity of PSMA
may have a key contributing role in glutamate production by PCa cells. PSMA is a type II
transmembrane glutamate carboxypeptidase and glutamate is the major constant product of
its enzymatic activity in PCa cells (28, 29). PSMA is overexpressed in PCa and high PSMA
expression is associated with advanced tumor stage, poor prognosis and high risk of
biochemical recurrence (28,30). PSMA-generated glutamate signaling may serve as a non-
androgenic regulator of PCa growth (31). Therefore, PSMA may have critical functions in
metabolomics profiling during prostate carcinogenesis and progression.
Analysis of the glutamate receptor, GRM1, in PCa cell lines showed a cell type-dependent
expression. GRM1 expression was higher in metastatic or androgen-independent PCa cell
lines (e.g., DU145, MDA-PCa2b, VCaP, 22RV1) than in the primary (i.e, E006AA) or
androgen-sensitive LNCaP cell lines. GRM1 overexpression might be an adoptive change
hypersensitizing PCa cells to extracellularly available glutamate or could confer oncogenic
activity due to its post-receptor signaling activation. Aberrant expression of GRM1 was
found sufficient for oncogenic transformation of melanocytes in transgenic mice (18, 19).
Overexpression of several members of mGluRs have been reported in other cancers (32-34).
Activation of mGluR-triggered signaling pathways may occur in response to free circulating
glutamate, glutamate released by tumor cells (autocrine loop), or stromal cells in the tumor
microenvironment (paracrine loop). The data presented here also support an intracrine
regulatory role for glutamate in PCa cell growth, migration, and invasion.
Intense nuclear staining was detected in basal cells of normal glands and in endothelial cells,
infiltrating macrophages, and stromal cells at the tumor-inflammatory interface or tumor
microenvironment. Moderate to intense cytoplasmic staining was detected in HGPIN, which
is considered to be a precursor lesion to PCa. Further examination of GRM1 expression in
primary and metastatic PCa tissue sections showed moderate to intense cytoplasmic staining
in malignant acinar cells with perinuclear enhancement in Gleason score ≤ 7 tumors and
intense but similar expression pattern in Gleason score ≥ 8 tumors and in highly aggressive
ductal adenocarcinomas (Supplementary Fig. S3). In addition, locally advanced PCa
produced intense cytoplasmic staining in PCa cells invading into extraprostatic adipose and
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muscular tissues, and in multi-layer tumor cells infiltrating around nerve cells. Intense
cytoplasmic staining with perinuclear enhancement was detected in metastatic PCa cells to
bone and the abdominal wall. Overall, the descriptive IHC analysis demonstrates GRM1
overexpression in primary and metastatic PCa tissues compared to non-cancerous and
benign tissues. Additional large-scale studies are required to assess the predictive or
prognostic significance of GRM1 expression in PCa.
Serum glutamate levels in mCRPCa were significantly higher in African-American patients
than Caucasian-American research subjects. Univariate analysis showed serum glutamate
levels affected by race (Table 1). Two covariate models adjusting for two potential
confounders revealed that age, PSA, race, and stage are not significant confounders (Table
2). However, when Gleason score was added to the model with race, age, and PSA, race had
a dominant effect and relationship with serum glutamate levels in African-American men.
Gleason score is the most reliable predictor of lethal PCa. Both groups showed significant
association between serum glutamate levels and Gleason score (≥ 6 versus ≤ 8). African
Americans with mCRPCa were found to have higher serum glutamate levels than in the
primary PCa. These data might reflect the small sample size for mCRPCa (n= 10) in African
American study cohort compared with the Caucasian Americans (n=99).
These data suggest that high serum glutamate levels may favor higher growth rates and
aggressive behavior for primary PCa in both racial groups and for mCRPCa in African
Americans. While inter-racial differences for metabolic genes have been reported in several
studies (35), large-scale studies are needed to determine the exact contribution of glutamate
either as a metabolic byproduct or a contributing factor in PCa-racial disparity.
First evidence for a link between glutamate receptor mGluR1 (GRM1) and tumorigenesis
was provided by an accidental discovery in which spontaneous melanoma in a transgenic
mouse line (TG-3) was discovered to be due to multiple tandem insertions of the transgene
into intron 3 of GRM1 leading to aberrant expression of GRM1 in melanocyte and the
development of melanoma at a high rate and young age (18, 19). This was verified in a
subsequent transgenic mouse line, TG(GRM1)Epv (E), in which GRM1 expression was
regulated by a melanocyte-specific promoter, dopachrome tautomerase (36). Different
pharmacologic agents have been used as GRM1 (i.e., mGluR1) agonist or antagonists.
Riluzole is an FDA-approved GRM1-blocking agent and well-tolerated oral medicine for the
treatment of amyotrophic lateral sclerosis that has been used to prevent glutamate release
(37). LY367385 or BAY36-7620 is known as competitive or non-competitive GRM1
antagonist, respectively (24, 38). Riluzole, BAY36-7620, or LY367385 prevent the growth
promoting effect and activation of signaling pathways by glutamate in a variety of cancer
cell types including melanoma and breast carcinoma (38, 39).
PCa cell proliferation was significantly reduced in a time-dependent manner in glutamate-
depleted medium or in the presence of GRM1 antagonists (Fig. 3A and B and
Supplementary Fig. S4). These data indicated that PCa cells growth depended on GRM1-
signaling. Riluzole inhibition of glutamate release and GRM1-signaling in PCa cells
cultured in complete growth medium not only decreased growth rate, but led to apoptotic
cell death, demonstrated by increased expression levels of cleaved caspase-9, -7, -and -3 and
PARP. These results were confirmed by the demonstration that phospho-H2AXSer139 levels
(known as γ-H2AX) appeared early during apoptosis. Initiation of DNA double-strand
breaks following caspase and apoptotic endonuclease activation induces phosphorylation of
H2AX histone at Ser139 (26).
The inhibitory effect of glutamate blockade on PCa cell proliferation and migration may be
at least partially mediated by the PI3K/Akt/mTOR pathway (6). The PI3K/Akt/mTOR
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function as the main regulator of aerobic glycolysis in malignant cells. Activation of the
PI3K/Akt/mTOR pathway in cancer cells triggers many of the metabolic activities that
support cellular biosynthesis such as (a) increased surface expression of nutrient transporters
leading to increased uptake of glucose and amino acid, (b) activated Akt increases glycolysis
and lactate production and induces a “Warburg effect” in cancer or even proliferating non-
transformed cells (40), (c) activation of PI3K and Akt induce lipogenesis and stimulate
lipogenic genes expression in a variety of cell types (41), and (d) mTOR serves as a major
regulator of protein translation.
A cell type-specific response to glutamate blockade suggests differential expression levels
for GRM1 in different PCa cells or their dependence on glutamate signaling. Excess
intracellular glutamate and/or inhibition of GRM1-signaling by riluzole treatment may have
deleterious effects on PCa cells growth, migration, and invasion which cannot be salvaged
by an intact extracellularly-activated GRM1-signaling. In addition, accessibility to a certain
amount of glutamate is essential for PCa cells growth that may signify “glutamine
addiction”. However, more than this necessary amount may lead to “glutamate-toxicity” and
activation of various interactive apoptotic signaling pathway leading to PCa cell-killing.
Intracellular glutamate as a metabolic intermediate, metabolic byproduct, or metabolic
regulator of interactive multiple signaling pathways may play a major role in malignancy.
Glutamate via a combination of intracrine, autocrine, paracrine pathways may contribute to
PCa growth and aggressiveness. Our data suggest that glutamate together with other
predictive or prognostic factors may be a useful metabolic marker for early detection and
clinical discrimination of aggressive tumors from non-aggressive tumors. Glutamate-
initiated signaling pathways may provide novel therapeutic opportunities for PCa.
Additional work is needed to ascertain the clinical and therapeutic implications of glutamate
dependence in PCa.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Aerobic glycolysis is a hallmark of proliferating normal and malignant cells. During
glutaminolysis, glutamine is catabolized to glutamate and incorporated into the citric acid
cycle and lipogenesis. Glutamate plays a substantial and overlapping role between
metabolic and oncogenic signaling pathways. In this study, we found that serum
glutamate levels were increased in primary PCa patients and directly correlated with
Gleason score and PCa aggressiveness. Compared with Caucasian Americans, serum
glutamate levels were higher in African Americans with mCRPCa than those with
primary tumors. Immunohistochemical staining showed weak or no expression of
metabotropic glutamate receptor 1 (GRM1) in normal prostate cells, but overexpression
in primary and metastatic PCa. Glutamate-deprivation or blockade with GRM1
antagonists reduced PCa cells’ growth, migration, and invasion and proved apoptogenic.
Glutamate may provide a metabolic biomarker of PCa aggressiveness and glutamine
metabolism or signaling may provide a target for therapeutic intervention.
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Figure 1. Box and whiskers plot of serum glutamate levels in normal individuals and patients
with primary or metastatic castrate-resistant PCa of Caucasian- or African-American origin
Serum glutamate levels were measured as described in “Materials and Methods”. The study
cohorts were analyzed according to their clinical status as normal research subjects, primary
PCa, or metastatic castrate-resistant PCa (left). All primary PCa patients were divided
according to their aggressiveness score based on Gleason and PSA (middle) or according to
Gleason score (right). A, The entire study cohorts. B, The entire study cohorts of Caucasian
Americans. C, The entire study cohorts of African Americans. Actual p-values are indicated
on individual graphs. The distribution of log-transformed serum measurements were
compared among groups using one-way ANOVA with Tukey pair-wise comparisons. The
box frame defines the 25-75 percentiles, the ends of error-bar like whiskers depict the
minimum and maximum values, and the line within the box marks the median value.
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Figure 2. Expression pattern of metabotropic glutamate receptor 1 (GRM1) in normal and
malignant prostate cancer tissues and cells
A, Representative immunohistochemistry results; magnification, x 200. Benign prostate
hyperplasia showing nuclear staining in basal cells and absence of staining in normal
luminal acinar cells. Intense nuclear and cytoplasmic staining is noted in vascular
endothelial cells (v), tissue infiltrating macrophages (mp), and stromal cells (s). Intense
cytoplasmic and nuclear staining is seen in an area of basal cell hyperplasia. Moderate to
intense cytoplasmic staining is noted in a representative image of high-grade prostate
intraneoplasia (HGPIN), with relatively absence of staining in most nuclei. Moderate to
intense cytoplasmic staining with perinuclear enhancement is noted in Gleason 6 (3+3) and
Gleason 7 (3+4) tumor. Intense cytoplasmic staining with perinuclear enhancement was
observed in malignant luminal acinar cells with Gleason 8 (4+4), Gleason 9 (5+4), and a
Gleason 10 tumor. Moderate cytoplasmic staining in a Gleason 3+4 tumor with intense
nuclear staining was observed in inflammatory (inf) and endothelial cells, and isolated
macrophage. Intense cytoplasmic staining was observed in tumor cells invading into
extraprostatic adipose (F) and muscle (M) tissues. Perineural invasion was noted by intense
cytoplasmic staining of multi-layer tumor cells circling around nerve cells (n). Neural
structures are negative for staining and the background stroma shows moderate focal nuclear
staining. Intense cytoplasmic staining with perinuclear enhancement is noted in scattered
bone-metastatic prostate cancer cells. Bone tissue appears as fragmented pieces. Intense
cytoplasmic staining was observed in malignant prostate cells metastasized into abdominal
wall. B, GRM1 protein expression in prostate cancer cell lines. Western blot analysis was
performed on whole-cell lysates by SDS-PAGE in the presence of reducing agent (upper
panel). The anti-GRM1 specificity was examined by probing a duplicate membrane with
primary antibody pre-incubated with 5 μg/ml blocking peptide for 2h (middle panel).
GAPDH detection was used for loading control. LNCaP = androgen-sensitive PCa cell line;
PC-3, DU145, MDA-PCa2b, VCaP, 22RV1 androgen-independent PCa cell lines; E006AA
= primary African American PCa cell line.
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Figure 3. Inhibition of prostate cancer cell growth by glutamate deprivation or GRM1-
antagonist
A, Effect of glutamate deprivation on PCa cells proliferation. Cells were seeded at 500
(PC-3, DU145, LNCaP) per 200 μl/well in 24 replicates in 96-well plates in their complete
medium. After 3 days, cells were incubated in their maintenance medium or customized
glutamine- and glutamate-free culture media supplemented with 10% dialyzed FBS and 2
mM Glutamax ™ for 3, 5, or 7 days. The media were refreshed every 48 h. Cell proliferation
was measured by adding 20 μl MTS solution per well for 1 h and measuring the absorbance
at 490 / 630 nm. bars, mean ± SEM, p < 0.001, Student t-tests were used to compare cell
growth between glutamate-free and complete medium at each day. One-way ANOVA test
with Bonferroni corrections was used to compare values among different days for each cell
line. B, Effect of GRM1-antagonist on PCa cells growth. Cells were seeded as described
above and were incubated in their complete medium in the presence or absence of riluzole at
10, 25, or 50 μM for 2, 4, or 6 days with media refreshment every 48h, followed by cell
proliferation assay as described above. Data represented the average of three independent
experiments ± SEM. Statistical significance (p < 0.0001) between the control and treatment
groups was evaluated by one-way ANOVA test with Bonferroni adjustment. C, Induction of
apoptosis by riluzole. Cells were cultured in their complete medium in the presence or
absence of riluzole as described above. Whole cell lysate were extracted and
immunoblotting was performed on 30 μg protein using antibodies against cleaved
caspases-9, -7, and -3, PARP, and phosphoserine-139 H2AX. Anti-GAPDH antibody was
used for control loading. Experiment was repeated twice independently.
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Figure 4. Effect of glutamate blockade on PCa cells migration and invasion
Cell migration and invasion was performed using 8-μm transwell filters. For the invasion
assay, the upper compartment was coated with 50 μg Matrigel per filter. A suspension of
cells (5 × 104 for PC-3 or 2 × 104 for DU145) in basal medium containing 0.1% BSA were
added to the upper compartment. The lower compartment was filled with 400 μl basal
medium containing 10% FBS as chemoattractant. Riluzole or BAY36-7620 was included at
equimolar concentrations (0 to 50 μM) to upper and lower compartments. After 48 h for
PC-3 or 24 h for DU145, migrated or invaded cells in transwell filters were counted from ten
randomly selected fields in at least four independent wells. Data represented the average of
three independent experiments ± SEM. Statistical significance (p < 0.05) between the
control and treatment groups was evaluated by one-way ANOVA test with Bonferroni
adjustment.
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